Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters
Ayşe Can, Panos Zanos, Ruin Moaddel, et al.
Journal of Pharmacology and Experimental Therapeutics (2016) Vol. 359, Iss. 1, pp. 159-170
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos, Ruin Moaddel, Patrick J. Morris, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 621-660
Open Access | Times Cited: 942
Mechanisms of ketamine action as an antidepressant
Panos Zanos, Todd D. Gould
Molecular Psychiatry (2018) Vol. 23, Iss. 4, pp. 801-811
Open Access | Times Cited: 895
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Chadi G. Abdallah, Gerard Sanacora, Ronald S. Duman, et al.
Pharmacology & Therapeutics (2018) Vol. 190, pp. 148-158
Open Access | Times Cited: 198
Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 163
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies
Thu Ha Pham, Alain M. Gardier
Pharmacology & Therapeutics (2019) Vol. 199, pp. 58-90
Open Access | Times Cited: 154
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 116
The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Convergent Mechanisms Underlying Rapid Antidepressant Action
Panos Zanos, Scott M. Thompson, Ronald S. Duman, et al.
CNS Drugs (2018) Vol. 32, Iss. 3, pp. 197-227
Open Access | Times Cited: 154
Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling
Laura Cavalleri, Emilio Merlo Pich, Mark J. Millan, et al.
Molecular Psychiatry (2017) Vol. 23, Iss. 4, pp. 812-823
Open Access | Times Cited: 130
Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine–Induced Sustained Antidepressant-like Effects
Thu Ha Pham, Céline Defaix, Xiaoming Xu, et al.
Biological Psychiatry (2017) Vol. 84, Iss. 1, pp. e3-e6
Closed Access | Times Cited: 119
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Todd D. Gould, Carlos A. Zarate, Scott M. Thompson
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 213-236
Open Access | Times Cited: 117
Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit
Ning Yao, Olga Skiteva, X Zhang, et al.
Molecular Psychiatry (2017) Vol. 23, Iss. 10, pp. 2066-2077
Open Access | Times Cited: 103
Classics in Chemical Neuroscience: Ketamine
Marshall Tyler, Harmony B. Yourish, Dawn F. Ionescu, et al.
ACS Chemical Neuroscience (2017) Vol. 8, Iss. 6, pp. 1122-1134
Closed Access | Times Cited: 96
Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
Michelle Kokkinou, Elaine E. Irvine, David R. Bonsall, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 6, pp. 2562-2576
Open Access | Times Cited: 89
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 2, pp. 763-791
Open Access | Times Cited: 75
Dual action of ketamine confines addiction liability
Linda D. Simmler, Yue Li, Lotfi C. Hadjas, et al.
Nature (2022) Vol. 608, Iss. 7922, pp. 368-373
Closed Access | Times Cited: 65
Ketamine and the Future of Rapid-Acting Antidepressants
Lace M. Riggs, Todd D. Gould
Annual Review of Clinical Psychology (2021) Vol. 17, Iss. 1, pp. 207-231
Open Access | Times Cited: 62
Ketamine and its metabolites: Potential as novel treatments for depression
Kai Zhang, Yitan Yao, Kenji Hashimoto
Neuropharmacology (2022) Vol. 222, pp. 109305-109305
Closed Access | Times Cited: 59
Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study
Si Qi Yang, Ying Zhou, Shu Yang, et al.
Journal of Affective Disorders (2023) Vol. 339, pp. 333-341
Closed Access | Times Cited: 31
Deep brain stimulation alleviates tics in Tourette syndrome via striatal dopamine transmission
Aaron E. Rusheen, Juan M. Rojas Cabrera, Abhinav Goyal, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 4174-4190
Open Access | Times Cited: 22
Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine
Kenichi Fukumoto, Michihiko Iijima, Takeo Funakoshi, et al.
The International Journal of Neuropsychopharmacology (2017) Vol. 21, Iss. 4, pp. 371-381
Open Access | Times Cited: 77
Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Laura Hondebrink, Anne Zwartsen, Remco H.S. Westerink
Pharmacology & Therapeutics (2017) Vol. 182, pp. 193-224
Open Access | Times Cited: 76
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Cristan Farmer, Jessica R. Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1398-1404
Open Access | Times Cited: 69
Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
Xavier López-Gil, Laura Jiménez-Sánchez, Leticia Campa, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 7, pp. 3318-3326
Open Access | Times Cited: 58
Page 1 - Next Page

Scroll to top